Skip to main content
Canna~Fangled Abstracts

Perception and Belief on Cannabinoids: A Comparative Study of Rheumatology Patients and Primary Care Physicians on the Use of Cannabinoids for Pain Management

By March 20, 2021April 13th, 2021No Comments
. 2021 Mar 7;13(3):e13756.

doi: 10.7759/cureus.13756.

Nibha Jain 1, Neelima Reddy Kunam 2, Arumugam Moorthy 3 1
Affiliations 

Abstract

Introduction: With the recent increase in popularity of cannabinoids in the management of chronic pain, the inquisitiveness among our patients and health care professionals are probably now at its peak. Many treating health care professionals in their clinical practice come across patients who either use cannabinoids or are interested in their efficacy and side effects. As there is paucity of data and research about their use in rheumatology, patient’s self-reported responses and experience of primary care physicians (General Practitioners [GPs]) can guide in expanding our knowledge. Methods Ours was an observational, cross-sectional study among rheumatology patients and GPs in the Leicestershire area. Initial questionnaire was designed by authors addressing demographics, knowledge, experience and perception. This was piloted among patients and GPs and improvised, redesigned and used for the study. The study design consisted of two arms: first arm including GPs and second arm rheumatology patients. Results Arm 1 consisted of 100 GPs with median age group of 30-40 years. 34% GPs experienced their patients inquiring about cannabinoids. 78% did not believe cannabinoids benefited the patients. On a scale of 0-10, the mean benefit in managing pain 3.2 + 2.5. Arm 2 consisted of 102 patients. 16% reported using cannabinoids for managing their chronic pain. The users reported significant improvement in pain compared to non-users (p=0.002). On comparing the perception of cannabinoids between GPs and patients, there was a statistically significant difference regarding awareness and effectiveness (p<0.001). Conclusion With the paucity of data and research about the use of cannabinoids in rheumatology, the patient self-reported responses provided an estimate as to their efficacy. This was significantly different from the GP perception. Disease and drug-focused research is need of the hour. To our knowledge, this is the First Single Centre study in the UK evaluating GP and rheumatology patient perception on cannabinoids.

 

Keywords: arthritis and orthopaedic rheumatology, chronic pain management, complementary alternative medicine, synthetic cannabinoids

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1

Figure 2

References

    1. Cannabinoids for the treatment of rheumatic diseases — where do we stand? Katz-Talmor D, Katz I, Porat-Katz B, et al. Nat Rev Rheumatol. 2018;14:488–498. – PubMed
    1. Cannabinoid receptor 2 as a potential therapeutic target in rheumatoid arthritis. Fukuda S, Kohsaka H, Takayasu A, et al. BMC Musculoskelet Disord. 2014;15:275–2014. – PMC – PubMed
    1. Activation of cannabinoid receptor 2 attenuates synovitis and joint distruction in collagen-induced arthritis. Gui H, Liu X, Liu LR, Su DF, Dai SM. Immunobiology. 2015;220:817–822. – PubMed
    1. NICE. Cannabis-based medicinal products. NICE Guideline 144. http://www.nice.org.uk/ng144 2019
    1. Home Office Circular 2018: Rescheduling of cannabis-based products for medicinal use in humans. Crime, Policing and Fire Group (CPFG) Drugs and Alcohol Unit. [Dec;2018 ];2018 5:2018.

Leave a Reply